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Millions of patients suffer fromdebilitating spinal cord injury (SCI) without effective treatments. Elevating cAMPpromotes CNS neuron
growth in the presence of growth-inhibitingmolecules. cAMP’s effects on neuron growth are partlymediated by Epac, comprising Epac1
and Epac2; the latter predominantly expresses in postnatal neural tissue. Here, we hypothesized that Epac2 activation would enhance
axonal outgrowthafter SCI.Using in vitroassays,wedemonstrated, for the first time, thatEpac2activationusinga specific soluble agonist
(S-220) significantly enhanced neurite outgrowth of postnatal rat cortical neurons andmarkedly overcame the inhibition by chondroitin
sulfate proteoglycans and mature astrocytes on neuron growth. We further investigated the novel potential of Epac2 activation in
promoting axonal outgrowth by an ex vivo rat model of SCI mimicking post-SCI environment in vivo and by delivering S-220 via a
self-assembling Fmoc-based hydrogel that has suitable properties for SCI repair. We demonstrated that S-220 significantly enhanced
axonal outgrowth across the lesion gaps in the organotypic spinal cord slices, compared with controls. Furthermore, we elucidated, for
the first time, that Epac2 activation profoundly modulated the lesion environment by reducing astrocyte/microglial activation and
transforming astrocytes into elongatedmorphology that guided outgrowing axons. Finally, we showed that S-220, when delivered by the
gel at 3 weeks after contusion SCI in male adult rats, resulted in significantly better locomotor performance for up to 4 weeks after
treatment. Our data demonstrate a promising therapeutic potential of S-220 in SCI, via beneficial effects on neurons and glia after injury
to facilitate axonal outgrowth.
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Introduction
No cure for spinal cord injury (SCI) exists due to the complex
injury nature. Obstacles to SCI repair include a lack of intrinsic
growth capacity of adult mammalian CNS neurons, cavity and
glial scar formation, and inhibitory molecules expressed at SCI
lesions including chondroitin sulfate proteoglycans (CSPGs) and
Nogo (Fawcett, 2006; Cregg et al., 2014). Multiple strategies have
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Significance Statement
During development, neuronal cAMP levels decrease significantly compared with the embryonic stage when the nervous system is
established. This has important consequences following spinal cord injury, as neurons fail to regrow. Elevating cAMP levels encourages
injured CNS neurons to sprout and extend neurites. We have demonstrated that activating its downstream effector, Epac2, enhances
neurite outgrowth in vitro, even in the presence of an inhibitory environment. Using a novel biomaterial-based drug delivery system in
the formof a hydrogel to achieve local delivery of an Epac2 agonist, we further demonstrated that specific activation of Epac2 enhances
axonaloutgrowthandminimizesglialactivationinanexvivomodelofspinalcordinjury,suggestinganewstrategyforspinalcordrepair.
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been developed to boost the intrinsic growth capacity of adult
CNS neurons but without translational success. For example,
neurotrophins enhance axonal regrowth into the lesion in rodent
SCI models, but their inability to overcome inhibitory molecules
makes them largely ineffective as a treatment (Hannila and Fil-
bin, 2008). In adult mice, genetic Klf7 overexpression enhances
corticospinal tract axonal regrowth into the lesion with pyrami-
dotomy (Blackmore et al., 2012) but fails to promote regrowth
beyond the lesion after SCI (Wang et al., 2017). Genetic PTEN
deletion promotes axonal regrowth beyond the lesion in rodent
SCI models (Danilov and Steward, 2015; Du et al., 2015; Zhou et
al., 2015), but potential oncogenesis and long-term harmful ef-
fects on neurons pose concerns (Gutilla and Steward, 2016;
Gutilla et al., 2016).
Elevating cAMP levels has been shown as one of the most
effective ways to promote axonal regeneration and functional
recovery in preclinical SCI research (Neumann et al., 2002; Qiu et
al., 2002; Nikulina et al., 2004; Costa et al., 2013). Moreover,
cAMP elevation overcomes inhibition on axonal outgrowth caused
by myelin-associated inhibitors (Siddiq and Hannila, 2015). How-
ever, targeting cAMP is unlikely to be translated to the clinic as it is
ubiquitously expressed, so itsmanipulationwill alter functions in all
types of cells. Therefore, a downstream target of cAMPmore local-
ized to neuronal cells may offer an alternative solution.
Traditionally, it was thought that cAMP solely signals through
protein kinase A (PKA) to manifest its effects on axonal regener-
ation. However, the development of more specific tools allowed
the identification of Epac, a guanine nucleotide exchange fac-
tor for Rap1, as an intracellular target, other than PKA, di-
rectly activated by cAMP (Cheng et al., 2008). Indeed, a recent
study showed that the cortical infusion of a PKA antagonist,
contrary to the traditional hypothesis, led to a significant in-
crease in functional recovery in rats with SCI, suggesting the
involvement of a different cAMP downstream effector in pro-
moting axon regeneration (Wei et al., 2016).
In our previous studies, knocking down intracellular Epac in
adult rat DRGneurons using siRNA led to a significant reduction
in neurite outgrowth that could not be rescued by the addition of
cAMP analogs (Murray and Shewan, 2008). In addition, chemo-
attraction assays showed that axons are similarly attracted to a
gradient of an Epac agonist as they are to a gradient of a cAMP
agonist (Murray et al., 2009). Furthermore, the addition of Epac
agonists to an in vitro SCI remyelination model significantly in-
creasedmyelination andneurite outgrowth comparedwith controls
(Boomkamp et al., 2014). Together, these studies suggest that Epac
could be the key protein mediating the positive effects of cAMP on
axonal growth and guidance in vitro (Murray and Shewan, 2008;
Murray et al., 2009; Peace and Shewan, 2011). Epac has two iso-
forms: Epac1 is widely expressed embryonically, whereas Epac2 is
restricted mainly to postnatal nervous tissue (Peace and Shewan,
2011), suggesting that targeting Epac2 could provide a neuron-
specific route for manipulation to enhance axonal growth.
Therefore, our hypothesis was that the elevation of Epac2 ac-
tivity by a specific agonist would enhance neurite outgrowth in
vitro and promote axonal outgrowth in an ex vivo model that
mimics the in vivo inhibitory environment after SCI. To achieve a
gradual, sustained, and local release of the Epac2 agonist in the
injury site, we explored the use of a novel self-assembling Fmoc-
based hydrogel as a depot that can be directly injected into the
injury site, thus representing a minimally invasive surgical pro-
cedure for future clinical translation (Zhu and Marchant, 2011;
Tukmachev et al., 2016).
Materials andMethods
All procedures involving the use of live animals and animal tissues were
performed in accordance with the UK Home Office (Scientific Proce-
dures) Act, 1986, and were approved by the local ethics committee of the
University of Aberdeen.
Cortical neuron culture. Cortices of Sprague Dawley rats at postnatal
days 0–1 (mixed sexes) were harvested as a source for culturing cortical
neurons. The tissue was dissociated enzymatically with 50 U/ml papain
(Worthington) in retinal buffer at pH 7.4 composed of 15 mM HEPES
(Sigma-Aldrich) buffered Hanks balanced salt solution (Invitrogen)
containing 300 M D-L cysteine (Sigma-Aldrich) and incubated at 37°C
for 30 min. The papain action was stopped by using 10% FBS (Thermo
Fisher Scientific), and cells were resuspended in Neurobasal medium
(Thermo Fisher Scientific) supplemented with 2% B-27 (Thermo Fisher
Scientific), 1%Glutamax (Thermo Fisher Scientific), and 100 U/ml pen-
icillin and 100 g/ml streptomycin (Sigma-Aldrich). Cortical neurons
were plated at 40,000 neurons/ml on round 13 mm glass coverslips
(BDH) coated overnight with 10 g/ml poly-D-lysine (PDL; Sigma-
Aldrich) and cultured for up to 48 h at 37°C in a 5% CO2/95% air
incubator (NU-581DE; Nuaire).
DRG neuron and explant cultures. DRGs were dissected from Sprague
Dawley rats at postnatal days 0–5 (mixed sexes), collected in Ham’s F12
medium (Thermo Fisher Scientific), and trimmed to remove roots. Ex-
plants were plated directly when needed. For dissociating DRG neurons,
ganglia were transferred to 1ml retinal buffer containing 50U/ml papain
as described above. The tissue was then transferred to 100 l Hanks
balanced salt solution containing 0.25 mg/ml trypsin inhibitor (Sigma-
Aldrich) and 50 g/ml DNase (Sigma-Aldrich), followed by trituration
using a Gilson P200 pipette until a single-cell suspension was achieved.
The dissociated neurons were diluted to the required density with Neu-
robasal medium supplemented as described above plus nerve growth
factor (100 ng/ml; Sigma-Aldrich). DRG neurons were plated at 5000
neurons/ml on 13mmcoverslips coated overnightwith PDL as described
above and 2 g/ml laminin (Thermo Fisher Scientific) and cultured for
up to 48 h at 37°C in a 5% CO2/95% air incubator.
Microglial and astrocyte cultures. Primary mixed microglia and astro-
cytes were cultured as previously described (Georgieva et al., 2018) from
the cortices of Sprague Dawley rats at postnatal days 3–6 (mixed sexes)
and plated on 10g/ml PDL (Sigma-Aldrich) coated 60mmPetri dishes
(Biofil Triple red TCD010060). After 4 d of incubation at 37°C in a 5%
CO2/95%air incubator, the presence of two layers of cells was confirmed:
one layer of astrocytes firmly attached to the surface of the dish and a
layer of microglia visible as large spherical bright cells on top of the
astrocyte layer. Formicroglia plating,mediumwas collected after a gentle
swirl, centrifuged at 200 g for 10min at 4°C and the pellet resuspended
in warm medium. The microglia suspension was plated on 18 mm un-
coated sterile glass coverslips and used the following day. For astrocyte
plating, oncemicroglial cells were collected, cultureswerewashed repeat-
edly with warm PBS and incubated with trypsin/EDTA 0.25% (Sigma-
Aldrich) for 5 min at 37°C. Trypsin action was stopped by addition of
10% FBS, centrifuged at 200 g for 10 min at 4°C, and replated in two
PDL-coated flasks. Cultures were maintained for 3 weeks to ensure mat-
uration of the astrocytes (Smith et al., 1990).Mediumwas changed every
2 d, and cells were split when confluent. Microglia and astrocytes were
maintained in medium composed of DMEM with 10% FBS and 100
U/ml penicillin and 100 g/ml streptomycin.
Soluble agonist and antagonist treatments for neurons in vitro. Soluble
agonist Sp-8-BnT-cAMPS (S-220) and antagonist ESI-05 (both Biolog)
were used according to themanufacturer’s instructions for specific Epac2
activation and inactivation in neurons, respectively. In some experi-
ments, chicken extracellular CSPGs (CC117; Sigma-Aldrich) were added
to culture media at 0.5 g/ml at the time of cell plating.
In vitro treatments for microglia and astrocytes.Mature astrocytes were
plated in 13 mm PDL-coated coverslips at a density of 45,000 cells/ml.
Microglia were plated in 18mmuncoated coverslip at a density of 70,000
cells/ml. Both cell types were allowed to attach and grow overnight. The
next morning, media were changed to serum-free media before treat-
ments. Three conditions were studied: control, lipopolysaccharide
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(LPS), and simultaneous LPS and S-220 treatment. Therefore, 10 g/ml
LPS was added to the media alone or together with S-220 at 2.5 M, a
concentration showing effects in promoting neurite outgrowth. The
treatments were left for 4 h.
siRNA transfection. For siRNA knockdown, DRG neurons were trans-
fected with 3 g of siRNA duplex (Epac2: ATC CGT GAA TGT AGT
CAT TTA) (QIAGEN) using the Amaxa Nucleofector II device (Lonza
Walkersville) according to the manufacturer’s instructions. To establish
transfection efficiency using this method, 3 g of 3-fluorescein-tagged
Allstars negative control siRNA (QIAGEN)was transfected into neonatal
DRG neurons, which were plated on 2 g/ml laminin-coated glass
coverslips. After 16 h, cells were fixed in 4% PFA (Sigma-Aldrich), im-
munolabeled using anti-GAP43, and analyzed using an AF6000LX mi-
croscope (Leica Microsystems). Fluorescein-labeled neurons were
compared with the total number of GAP43-positive neurons to obtain
the transfection efficiency, which was calculated as 80%.
Lentiviral vector (LV) production.We had technical limitations for the
construction of LVs carrying the specific Epac2 cDNA because the avail-
able sequencewas not suitable for the subcloning in the lentiviral transfer
vector. Therefore, as a proof of concept, we constructed Epac-LV as
follows. Human Epac1-YFP construct was kindly provided by Dr. Kees
Jalink at The Netherlands Cancer Institute (Amsterdam, The Nether-
lands). hEpac1-YFP cDNAwas subcloned downstream of the CMV pro-
moter in the lentiviral transfer vector pRRL. Self-inactivating LVs were
made by cotransfecting HEK293T cells using a three-plasmid system
(Dull et al., 1998). pRRL/hEpac1-YFP or pRRL/GFP plasmids were
transfected together with pPACK and pENV plasmids using the calcium
precipitation method (Dull et al., 1998). Lentiviral particles were har-
vested 45 h after transfection and concentrated using polyethylene glycol
precipitation. Viral particles were resuspended in sterile PBS after pre-
cipitation. The titers were determined by transduction of HEK293T cells
using serially diluted viral stocks. The titers were 4.6  109 TU/ml for
LV/hEpac1-YFP (referred as LV/Epac hereafter), and 2.2  109 TU/ml
for LV/GFP. The viral stocks were aliquoted and stored at80°C. Cor-
tical neurons to be transduced with the LV were plated in 24 well plates
(Greiner) at a density of 60,000 cells/ml; 2.2  106 TU of LV/GFP or
LV/hEpac1-YFP was added per well to allow transduction. Media were
replaced the day after and then changed every 2 d. Cells were maintained
for 7 d to ensure full expression of the transgenes. Anti-GFP-labeled
neurons were compared with the total number of -tubulin-(III)
-positive neurons to obtain the transduction efficiency.
FRET SE microscopy. Fluorescent resonance energy transfer sensitized
emission (FRET SE) was performed in live DRG neurons as previously
described (Tucker, 2014). FRET SE microscopy allowed us to demon-
strate the level of Epac2 protein activity in the presence of the agonist,
S-220, or the antagonist, ESI-05, respectively, in the growth cones of live
DRG neurons. Two fluorophores (CFP and YFP) were fused to the two
termini of Epac2 protein in the Epac FRET construct (see below). When
the distance between the two is10 nm, which occurs when the protein
is inactive, a FRET signal is produced. On activation of the protein, a
conformational change occurs and the distance between the two fluoro-
phores becomes10 nm, abolishing the FRET signal. Thus, high FRET
signals correlate with low Epac2 activation and low FRET signals corre-
late with high Epac2 activation. Briefly, neurons were transfected with
the construct mTurqDel-Epac (dDEPCD) cp173Venus (d)-Venus (d)
(H74) (Klarenbeek et al., 2011) (kindly provided by Dr. Kees Jalink, The
Netherlands Cancer Institute, Amsterdam, The Netherlands) using the
Amaxa Nucleofector II device (Lonza Walkersville). The cells were di-
luted in medium after transfection and cultured in 50 mm glass-
bottomed dishes (MatTek) coated with PDL and 5 g/ml laminin. One
day after transfection, the medium was topped up to 5 ml and buffered
with 15 mM HEPES buffer. Using an AF6000LX imaging system (Leica
Microsystems) configured correctly for FRET, images were taken of a
selected growth cone in theCFP, YFP, and FRET channels every 2min for
a total of 30 min. For each experiment, the first four images were taken
without application to act as a baseline as the system stabilized; then the
reagent was added after the fourth time point. The Epac2 agonist (S-220)
was diluted to a concentration of 5 M and the antagonist (ESI-05) to 10
M. Analysis of each image (combining all 3 channels) was performed
using Application Suite-Advanced Fluorescence software (Leica Micro-
systems) by selecting a “region of interest” within the growth cone and
recording the FRET value. These data were then expressed as a percent-
age change from time 0.
Choice assay. Mature astrocytes obtained as described above were
plated at 5000 cells/ml on 5 g/ml laminin custom-made dishes. These
dishes consisted of 60 mm Petri dishes (CellStar, Greiner Bio-One) that
had three 13-mm-diameter holes in the base of the dish using a hole
puncher; 18mm coverslips weremounted onto the base of the dish using
RTV 3140 coating glue (Dow Corning) that is nontoxic to cells. Astro-
cytes were left to grow for 5 h before plating of DRG neurons among the
astrocytes. Cocultures were further incubated at 37°C overnight in a CO2
incubator. S-220 was added just before time lapse imaging. Time lapse
recordings were taken over 30–60 min using NIS-element software and
an Okolab chamber-mounted eclipse Ti inverted microscope (Nikon).
The response of each DRG neurite was categorized into two different
categories: crossover and reflect/retract. Each response was calculated
as a percentage of the total number of interactions in each experimen-
tal condition, control or S-220 treatment. Data were collated for at
least 10 growth cones per condition and pooled from at least 3 sepa-
rate experiments.
Growth cone turning assays. Assays were performed as previously de-
scribed (Murray and Shewan, 2008). Briefly, DRGneuronswere cultured
in low-walled glass-bottomed 50 mm Petri dishes (MatTek) coated with
5 g/ml laminin. The culture medium, supplemented with 15 mM
HEPES buffer, was overlaid with a thin monolayer of warmed vegetable
oil and transferred to a Nikon Diaphot inverted-stage microscope
equipped with a stage-mounted incubator heated to 37°C. Growth cones
were visualized using aNikonDiaphot invertedmicroscope connected to
a PC runningQWin version 2.1 software (LeicaMicrosystems). Borosili-
cate glass micropipettes (Intracel) were pulled in a Sutter pipette puller
(Intracel) so that they had a bore width of 1 m. Growth cones were
oriented at 45° and 100 m from a glass micropipette containing 3–5 l
of either F12 as a control or S-220 treatment. Each reagent was ejected by
an air pulse of 3 psi at 2 Hz and 10 ms duration, applied to the pipette by
a Picospritzer III (Intracell). Each growth cone was assayed for 30 min,
and only growth cones that had advanced at least 10mfrom the original
position at time 0 were included. The angle between the position of the
growth cone at 30 min, its original position at time 0, and its original
direction of growth was calculated using ImageJ software. Data were
collated for at least 10 growth cones per condition, pooled from at least 3
separate experiments.
Hydrogel characterization. Fmoc hydrogel is commercially available
(BiogelX) and can also be made using published methods (Alakpa et al.,
2016). Hydrogel was prepared at 2.2 mg/ml using ThinCert cell inserts
(Greiner Bio-One) and following the manufacturer’s instructions. RGD
(Arg-Gly-Asp) peptide (ab142698; Abcam) at different concentrations
was incorporated into the gel according to the manufacturer’s instruc-
tions. Rheology experiments (Discovery HR-2, TA Instruments) were
performed at different time points during degradation to assess changes
in gel stiffness, using Frequency sweep test 0–100 Hz, 1% strain at 37°C.
Gels were also weighed at different time points during degradation in
PBS. Buffer was completely aspirated, and the insert weight was sub-
tracted from the total weight. The Griess assay was used to quantify
nitrite release by primary microglia when cultured with the hydrogel for
6 h. LPS (1 g/ml; Sigma-Aldrich) was used as a positive activated con-
trol. Fluorescein sodium salt (Sigma-Aldrich) was used to assess the re-
lease profile since it has similar molecular weight compared with S-220
(MW 376.27 Da) and can be measured by a fluorescence plate reader
(Omega microplate reader; BMG Labtech) at 440–520 nm with 700 ms
gain (Perale et al., 2012; Wilems and Sakiyama-Elbert, 2015).
Immunocytochemistry. Cells and explants were fixed with 4% PFA in
PBS for 30min, followed by incubation with 10% normal goat serum for
1 h, all at room temperature. Cells/explants were then incubated with
primary antibodies overnight at 4°C. We used the following primary
antibodies: anti--tubulin-III (1:1000, mouse; RRID:AB_1844090;
Sigma-Aldrich), anti-growth associated protein-43 (GAP-43) (1:500,
rabbit; RRID:AB_10622060; Sigma-Aldrich), anti-glial fibrillary acidic
protein (GFAP) (1:1000, mouse; RRID:AB_94844; Merck Millipore),
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anti-ionized calciumbinding adaptormolecule-1 (Iba-1) (1:1000; rabbit;
RRID:AB_2314666; Wako), anti-inducible nitric oxide synthase (iNOS)
(1:100; mouse; RRID:AB_397719; BD Biosciences), and anti-GFP (1:
100, chicken; RRID:AB_300798; Abcam). Following three washes with
PBS, cells/explants were incubated for 2 h at room temperature with
the appropriate secondary antibodies, including goat anti-mouse,
anti-rabbit, or anti-chicken antibodies (1:400, RRID:AB_221544,
AB_221544, AB_143160, AB_141672, and AB_141359, respectively; In-
vitrogen). Coverslips were mounted with PBS/glycerol (1:8 ratio) after
counterstaining with Hoechst 33342 (2 g/ml in PBS; Sigma-Aldrich).
All primary/secondary antibodies and goat serum were prepared with
PBS containing 0.2% Triton X-100 (Sigma-Aldrich) and 0.1% sodium
azide (Sigma-Aldrich).
Imaging and quantification for neurite outgrowth. An Eclipse Ti-E mi-
croscope (Nikon) was used to acquire all images. HCA-vision (CSiRO)
was used to quantify total neurite length. The pluginNeuron J for ImageJ
was used to manually quantify Maximal Neurite Length of dissociated
neurons and maximal distance (Dmax) of neurite growth from DRG ex-
plants (Torres-Espín et al., 2014). Analyses were performed for at least
100 neurons and 10 DRG explants per condition from three different
experiments.
Analysis of astrocytes and microglia activation in vitro. For each cover-
slip, 10 representative micrographs were taken with a 20 objective. A
minimum of 100 cells per condition were analyzed. The activation of the
astrocytes was determined by the quantification of GFAP intensity (So-
froniew, 2009). All images were converted into 8-bit files, and the func-
tion threshold in ImageJ was applied to select only area with GFAP
immunoreactivity. Intensity of staining was determined by the mean
optical density value. The mean background fluorescence proximate to
each cell was subtracted from the measured fluorescence intensity of the
cell area to give a corrected fluorescence intensity. The activation of
microglia was quantified by calculating the percentage of iNOS/Iba-1
double-immunoreactive cells in the total Iba-1-immunoreactive cells.
Data for same conditions from three different replicates were averaged
and compared.
Production of spinal cord slices: ex vivo modeling of SCI. The ex vivo
model using rat spinal cord tissue was adapted from a study usingmouse
spinal cord tissue (Weightman et al., 2014). The SDpup’s (postnatal days
0–3; mixed sexes) dorsal trunk skin surface was sprayed with 95% etha-
nol; then a dorsalmidline incisionwasmade and skin flapswere retracted
to expose the spinal column. A midline incision was made along the
length of the spine using fine micro-dissecting Vannas spring scissors
(Fine Science Tools). The spinal cord was rapidly dissected from the
thoracolumbar region and placed in ice-cold slicing media. The menin-
ges were gently removed, and a 0.7–0.9 cm length of cord was cut from
the thoracic region. The cord was transferred onto an ice-cold chopping
plate of a preset McIlwain tissue chopper and sliced lengthways in the
parasagittal plane (350 m thickness). Three or four slices could be
derived from each cord. Slices were incubated in ice for 90 min and then
selected under a dissectingmicroscope and transferred to precutOmnip-
ore membrane “confetti” (Merck Millipore), resting on the Mill cell
culture insert membrane (Merck Millipore), using a plastic Pasteur pi-
pette. The process of slice plating was performed under a dissecting mi-
croscope to ensure the correct position of the slice. To avoid variability,
the selected slices from each pup were plated together in one dish fitting
up to four slices. Slices were cultured at the air–medium interface for up
to 10 d in a humidified incubator with 5% CO2 at 37°C with 80% me-
dium changes every other day. The experimental unit, n, refers to slice
numbers obtained from different pups.
Lesioning organotypic spinal cord slice cultures. Cords were lesioned
after 3 d in culture. A slice lesioning tool was custom-made using a
preassembled, double-bladed scalpel with a spacer creating a gap of700
m. The tool was aseptically assembled before lesioning by taping to-
gether two surgical blades (size 15) with a spacer in the middle secured
into a scalpel holder. The same lesioning tool was used in each individual
experiment. The lesioning procedure was implemented inside a horizon-
tal laminar flowhoodunder a dissectingmicroscope. To stabilize the slice
in the process of lesioning, the confetti was cut in a T shape, allowing it to
be secured with forceps while producing the lesion. A small lateral move-
ment was used to ensure complete transection of the cord without dam-
aging the confetti. An aspirator fitted with a pipette tip was used to
remove all the debris resulting from the lesioning.
Assessment of the viability of spinal cord slices. To assess viability, three
intact slices were randomly chosen before and after the lesion and incu-
bated with the live/dead assay kit (Invitrogen) containing calcein (1 l/
ml) for live cells and ethidium bromide (3 l/ml) for dead cells, for 15
min at 37°C. Following the incubation period, slices were mounted with
antifade mounting media Vectashield (Vector Laboratories). Immedi-
ately afterward, fluorescence micrographs were taken (664 m  834
m) with a 10 objective with consistent exposure settings and con-
verted to grayscale. The integrated density (mean gray value per unit
area) was measured from both live- and dead-stained micrographs.
Thus, the viability for each slice was calculated by expressing the cor-
rected integrated density of the live-stained micrograph as a percentage
of the sum total from both stained groups (Cho et al., 2009). The quan-
tification was conducted using ImageJ software.
Treatment of spinal cord slice. Treatment was administered immedi-
ately after the lesion either in the medium or incorporated into the gels.
Treatment gels were prepared 2 h before lesioning and precut into 700
m  700 m pieces using the McIlwain tissue chopper. Gels were
incorporated into the injury site under the microscope using needles.
Treatment was applied for 7 d.
Immunohistochemistry. All slices were fixed with 4% PFA 7 d after the
lesion for 30 min, followed by incubation with 10% normal goat serum
for 1 h at room temperature. Slices were then incubated with primary
antibodies for 24 h at 4°C. Primary antibodies used were as follows:
anti--tubulin-III (1:1000, mouse), anti-GFAP (1:500, rabbit; RRID:
AB_2109645; Merck Millipore), anti-GFAP (1:1000, mouse), anti-
Nestin (1:400, mouse; RRID:AB_2151130; Merck Millipore), and anti-
Iba-1 (1:1000; rabbit). Following three washes with PBS, cells were
incubated for 4 h at room temperature with appropriate secondary anti-
bodies, including goat anti-mouse or anti-rabbit secondary antibodies.
Slices were mounted with Vectashield. All primary/secondary antibodies
and goat serum were prepared with PBS containing 0.2% Triton X-100
and 0.1% sodium azide.
Image and axonal outgrowth analysis on spinal cord slices. All fluores-
cence images were captured with an Eclipse Ti-E microscope (Nikon).
Single panoramic images were generated when appropriate using the
Large Image tool in Nis Elements for advanced research software. Max-
imal Intensity Projection images using multiple Z planes were also used
when appropriate. Where applicable, fluorescence images of immuno-
stained slices were merged using Photoshop. Quantitative analysis of
-tubulin-III stained profiles was conducted across the lesion gap from
one lesion margin to the other according to previously published meth-
ods (Weightman et al., 2014), with 20 division lines at an equal distance
of 35 m between each line using a multiselection plugin from ImageJ.
Peak analysis plugin from ImageJ was then used to convert the staining
into optical density at each division line covering the whole width of the
lesion gap, which is equal to the width of the slice. Finally, the peaks
(number of staining profiles) per squaremillimeter per slice (Weightman
et al., 2014) were calculated by averaging the optical densities and then
divided by the area of the lesion gap.
Analysis of astrocyte activation in spinal cord slices.Quantitative analysis
of astrocyte activation was conducted by semiquantification of GFAP
staining intensity within the lesion gap. Thus, three fluorescence images
(478m 598m)were takenwith a 20objective from the front areas
of the GFAP-immunoreactive glial scar from one-half of the lesion first:
the central one aligned with the midline perpendicular to the lesion
margin and then one right and one left with equal distance of 200 m
from the central one. We then repeated with another three fluorescence
images for the other half of the lesion as described above. Consistent
exposures were applied for all captured images, which were then con-
verted to grayscale followed by applying a threshold using the ROI man-
ager plugin from ImageJ. Finally, the intensity of the GFAP staining from
the six images per slice was averaged.
Reactivity of astrocytes was also estimated by the overlapping of GFAP
and Nestin as previously described (O’Neill et al., 2017). Thus, three
fluorescence images (478 m 598 m) were taken with a 20 objec-
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tive from the front areas of the GFAP-Nestin-
immunoreactive glial scar from both halves of
the lesion as described above. Briefly, captured
images were converted to grayscale followed by
the application of the “auto-threshold” func-
tion using the “Default” setting in ImageJ. This
generates a binary imagewith a black signal in a
white background. “Image Calculator” func-
tion in ImageJ using the “AND” operation was
used to generate a third image representing the
regions of overlap between binary green and
red. The number of overlapping pixels was cal-
culated by using the “Histogram” function in
ImageJ to obtain the total number of pixels
with value 255 (black). A minimum of three
images was analyzed per spinal cord slice and
averaged to get a final value per slice.
Analysis of microglial activation in spinal cord
slices. Quantitative analysis of microglial acti-
vation was conducted by semiquantification of
the cell body perimeter of Iba-1-immunore-
active cells within the lesion gap. Thus, three
fluorescence images (316 m 395 m) were
taken with a 30 objective as described above
for astrocyte activation analysis. The perimeter
(Kozlowski and Weimer, 2012) of at least 20
Iba-1-immunoreactive cells per micrograph
was then measured using ImageJ and averaged
for each slide. For nonlesioned microglial acti-
vation analysis, three images were taken from
at least 1 mm away from the lesion site, where
Iba-1-immunoreactive cells displayed nonre-
active morphologies.
Treatment of contusion injured spinal cord
with S-220-loaded hydrogel. For all in vivo ex-
periments, young male adult Wistar rats
weighing between 180 and 200 g were pur-
chased fromEnvigo. The skin andmuscle over-
lying the spinal column were incised, and a
laminectomy was performed between the T9
and T10 levels. Following fixation of the adja-
cent T9 and T11 vertebral body to suspend the
target region, a standardized moderate (12.5
mm) thoracic spinal contusion was inflicted at
T10 thoracic vertebral level by the use of aNYU
impactor device (Mascis rat model III; Rutgers
University) as previously described (Young,
2002; Kjell and Olson, 2016). Following the in-
jury, muscle layers were sutured and the skin
was closed. Postinterventional care included
manual voiding of the bladder twice a day until
voiding reflex was regained. Three weeks after
the induction of the injury, rats were randomly allocated to treatment
groups. For rats receiving treatment, a 10 l Hamilton syringe was
loaded with the pregel format of the hydrogel using RN 26S gauge
needle (26S/102/pst2/tapY) (Hamilton; Supelco). The Hamilton sy-
ringe was mounted on a stereotaxic frame and armed into 45° angle.
The dura was opened, and the needle was introduced into the dura
with the fine controllers. A maximum of 3 l was injected at1 l/min.
The needle was left in place for 10 min after injection to prevent the
leakage of the pregel solution. The dura was covered with a piece of
saline-soaked gel foam, muscle layers were sutured and the skin was
closed. Buprenorphine (0.3 mg/kg; Vetergesic; Alstoe Animal Health)
was given subcutaneously for the management of acute pain after
surgery and saline (0.9% NaCl, 5 ml) was administered subcutane-
ously to compensate for any blood loss. Locomotor function was
assessed by two observers independently using the 21-point Basso,
Beattie & Bresnahan (BBB) open field locomotor scale on postoper-
ative days 1, 3, 14, 21, 28, 35, 42, and 49.
Statistical analysis. Sigma-Aldrich Plot 13.0 andOrigin Pro 2018b soft-
warewas used for all statistical analyses. The normality test Shapiro–Wilk
was performed to ensure normal distribution of the data and suitability
of parametric tests. Equal variance was tested using the Brown–Forsythe
test. Statistical analyses were performed using unpaired Student’s t test
and one-way ANOVA, using Bonferroni’s multiple-comparison test for
post hoc analysis. If normality was not met, nonparametric tests were
used: theMann–Whitney rank sum test and the Kruskal–Wallis one-way
ANOVA on ranks with Dunn’s method or Tukey test post hoc correction.
For in vitro studies, all data represent mean	 SEM.
For ex vivo studies, between 4 and 6 replicates were done per condition
and experiment and are represented by a circle in the quantification
graph. All values quoted are expressed as themean	 SEM (box limits)	
5%–95% (error bars). Two-way repeated-measure ANOVA was per-
formed for locomotor recovery (BBB scale) analysis, followed by Bonfer-
roni’s post hoc multiple-comparison adjustment to calculate the
significant levels. “Treatment” is a between-subjects variable, whereas
“time” is a within-subjects variable. The in vivo data were presented as
Figure 1. The effects of Epac2 modulation on cortical neurite outgrowth. A–C, Epac2 agonist S-220 promoted significant
neurite outgrowth. A, Control. B, Treated with S-220. C, Quantification of total neurite length shows that S-220-treated
neurons had significantly longer neurites.D–F, Epac2 antagonist ESI-05 significantly decreased cortical neurite outgrowth.
D, Control. E, Treated with ESI-05. F, Quantification of total neurite length shows that ESI-05-treated neurons had signif-
icantly shorter neurites. G–I, siRNA knockdown of Epac2 significantly decreased cortical neurite outgrowth. G, Scrambled
siRNA control. H, Epac2 siRNA-treated. I, Quantification of total neurite length shows that Epac2 siRNA-treated neurons
had significantly shorter neurites. J–L, Overexpression of Epac protein using lentivirus promoted cortical neurite out-
growth. J, LV/GFP-transduced neurons. K, LV/Epac-YFP-transduced neurons. L, Quantification of total neurite length
shows that LV/Epac-YFP-transduced neurons had significantly longer neurites. A, B, D, E, Cultures were grown for 24 h. G,
H, Cultures were grown for 48 h. J, K, Cultures were grown for 7 d to allow enough time for gene expression. All cultures
were immunostained for -tubulin-III. Unpaired Student’s t test: *p 0.05; **p 0.01; ***p 0.001. n 3/group.
Data are mean	 SEM. Scale bars: A–E, J–K, 50m; G, H, 100m.
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mean 	 SEM. All statistical analyses were performed using Origin Pro
2018b and SigmaPlot 14.0 software.
Results
The elevation of Epac2 activity enhances neurite outgrowth
in vitro
Axonal repair following SCI requires the restoration of relays
from higher brain centers, such as corticospinal tracts, as well as
ascending sensory pathways relaying in-
formation from the periphery to the
brain.We have expertise inmodel systems
involving cortical neurons and DRG neu-
rons and have used both neuronal types in
the current study.
Using cultured postnatal rat cortical
neurons, we found that neurite outgrowth
(i.e., mean total neurite length per neu-
ron) was significantly enhanced by the
treatment of S-220 at 2.5 M for 24 h,
compared with that of the controls (ago-
nist vs control: 97.5 	 4.1 vs 72.8 	 2.6
m, p 0.0002, unpaired Student’s t test;
Fig. 1A–C). Moreover, neurite outgrowth
was significantly inhibited by bath appli-
cation of ESI-05 at 10 M for 24 h in cul-
ture (antagonist vs control: 50.1 	 4.8 vs
77.8 	 4.8 m, p  0.018, unpaired Stu-
dent’s t test; Fig. 1D–F). Furthermore, we
used genetic tools, such as siRNAandLVs,
to illustrate the importance of Epac for
neuronal growth. Thus, cortical neurons
subjected to specific Epac2 siRNA knock-
down for 48 h showed significantly
shorter total neurite length in comparison
with that of the controls (siRNA vs con-
trol: 131.4	 19.9 vs 183.3	 24.3m, p
0.018, unpaired Student’s t test; Fig. 1G–
I). Similar results were also obtained for
postnatal rat DRG neurons when they
were treated with the S-220 (S-220 vs con-
trol: 991.9	 202.9 vs 399.2	 101.4 m,
p  0.005787, unpaired Student’s t test;
data not shown) or when they were trans-
fected with Epac2 siRNA (siRNA vs con-
trol: 889.7	 49.9 vs 1677.9	 105.6 m,
p 1.1 1011 unpaired Student’s t test;
data not shown). Cortical neurons were
transduced with LVs (96.7	 3.4% trans-
fection efficiency) and left to grow for 7 d
to ensure protein expression. Neurons
transfected with LV/Epac-YFP had signif-
icantly more neurite outgrowth com-
pared with that of LV/GFP-transduced
neurons (LV/Epac-YFP vs LV/GFP:
1229.2 	 20.0 vs 795.2 	 110.4 m, p 
0.003, unpaired Student’s t test; Fig. 1J–L).
Epac2 agonist activates Epac protein in
DRG growth cones and attracts
growth cones
To demonstrate the activation/deactiva-
tion of Epac protein by the soluble agonist
S-220 and antagonist ESI-05 in neuronal
growth cones, we performed FRET SEmi-
croscopy, which allowed the visualization of protein dynamics in
situ (Tucker, 2014). DRG neurons were transfected with
mTurqDel-EPAC (dDEPCD) cp173Venus (d)-Venus (d) (40%
transfection efficiency) and allowed to grow for 48 h before the
experiments were performed. We found that there was a signifi-
cant increase of Epac activation in growth cones during the 30
minwhen the S-220was applied (S-220 vs baseline, p 8 108,
Figure 2. Epac agonist activates Epac protein in DRG growth cones and induces growth cone attraction. A–D, Representative
images of FRET SE before (A) and after (B) the addition of the Epac2 agonist S-220 and before (C) and after (D) the addition of the
Epac2 antagonist ESI-05. E, FRET SE measured over time shows a significant activation and inactivation of Epac after the addition
of the S-220 (blue) and ESI-05 (red), respectively, compared with control (black) (n 4). F, G, Representative images of DRG
growth cones turning toward a gradient of S-220 at time 0 (F ) and 30 min (G). H, Cumulative frequency plots of turning angles
show a clear switch toward the right in gradients of S-220 (blue) compared with control F12 (black), indicating greater attraction
toward thedirectionof Epac2activity. Average turningangles are shownabove theabscissa (n10). Data aremean	SEM. Scale
bars: A–D, 10m; F, G, 50m. *p 0.05; **p 0.01; ***p 0.001.
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unpaired Student’s t test; Fig. 2A,B,E). Conversely, when ESI-05
was applied, we found significantly reduced Epac activation in
the growth cones compared with the baseline (ESI-05 vs baseline
Epac2, p 0.001, unpaired Student’s t test; Fig. 2C,D,E). Using
the growth cone turning assay, we examined the effect of asym-
metric Epac2 activation on neonatal rat DRGneurites by creating
a gradient of the S-220 agonist. Figure 2H showed that neonatal
DRG growth cones displayed a random response to a gradient of
Figure3. The Epac2 agonist overcomes inhibitory environments for cortical neuron growth.A,-tubulin-III-positive cortical neurons grewneurites on PDL-coated coverslips.B, Cortical neurons
treated with CSPGs showed significantly shorter neurite lengths compared with control. C, Epac2 agonist S-220 attenuated the inhibitory effect of CSPGs on cortical neurite outgrowth. D,
Quantification represents thepercentageof change fromcontrol and showsa significant reduction in inhibitionbyCSPGswhenS-220was simultaneously applied. Culturesweregrown for 48h.E–G,
S-220 also showed the effect in overcoming the astrocyte inhibition. Three neurite growth cone behaviors of DRG neurons cocultured with mature astrocytes were observed: retract (E,ƒ), reflect
(E, *), and crossover (F, #) using time-lapse live cell microscopy. Green color (E,F) GFAP staining; Red color (E,F)-tubulin-III staining. G, Quantification showed a significant reduction in the
retract/reflect behaviors of neurites anda significant increase in the crossover behavior of neurites in cells treatedwith theEpac2agonist comparedwith control.D,G,Mann–WhitneyRankSumtest:
*p 0.05; **p 0.01. n 3/group. Data are mean	 SEM. Scale bars: A–C, 50m; E, F, 25m.
Figure4. Epac2 agonist S-220 attenuates LPS-induced astrocyte andmicroglial activation in vitro. Representative fluorescent images of control (A), LPS-treated (B), and LPS
 S-220-treated (C)
astrocytes (immunostained for GFAP). Representative fluorescent images of control (D), LPS-treated (E), and LPS
 S-220-treated (F )microglia immunostained for Iba-1 (green) and iNOS (red).G,
Quantification of the mean fluorescence intensity of GFAP showed significant difference between control and LPS-treated astrocytes, and between LPS and LPS
 S-220-treated astrocytes. H,
Quantitative imageanalysis showing significant differences in iNOS-immunoreactive cell numbers among control, LPS-treated, andLPS
S-220-treatedmicroglia. I, TheGriess assaydemonstrated
a significant increase of nitrate concentration in the supernatant collected from LPS-treated microglial cultures compared with that of the control. Data are mean	 SEM. n 3/group. One-way
ANOVA with Bonferroni post hoc test: ***p 0.001. Scale bars, 100m.
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F12 culture media emitted from a micropipette placed at a 45°
angle to the initial orientation of the projecting growth cones,
with a mean turning angle of 1.92 	 0.05° at 30 min. In con-
trast, growth cones displayed a strong chemoattraction when
S-220 was emitted from the pipette (Fig. 2F,G), and the mean
turning angle of 12.7 	 4.1° at 30 min was significantly greater
than that of F12 culture media (p 0.045, unpaired Student’s t
test; Fig. 2H).
The elevation of Epac2 activity overcomes inhibitory effects
on cortical neuron growth in vitro
To further explore the potential of Epac2 activation as a promis-
ing strategy to promote axonal outgrowth in the post-SCI envi-
ronment, we cultured postnatal rat cortical neurons together
with CSPGs, which significantly inhibited the outgrowth of cor-
tical neurons by 32.1 	 8.7% compared with the controls (p 
0.003, Mann–Whitney Rank Sum test; Fig. 3A,B,D). S-220 treat-
ment was able to overcome the inhibitory effect of CSPGs on the
mean total neurite length per cortical neuron (CSPGs
 S-220 vs
CSPGs: 32.1 	 8.7% vs 8.7 	 3.3%, p  0.007, Mann–Whitney
Rank Sum test; Fig. 3B–D). We then analyzed the response of the
growth cones of DRGneurons when they encountered inhibitory
mature astrocytes. This assay was performed in DRG neurons as
it was optimized for this primary neural type. The growth cones
had the choice of either growing over astrocytes or remaining on
the laminin substrate during a period of 30 min time lapse.
Growth cone response behaviors were classified into two catego-
ries: retract/reflect and crossover, respectively (Fig. 3E,F). When
S-220 was added to the cocultures, we found a significantly
increased proportion of growth cones growing over astrocytes
compared with that of the controls (S-220 vs control: 45.7 	
10.3% vs 11.2	 4.2%, p 0.0216, unpaired Student’s t test; Fig.
3G). Conversely, we found a significant reduction in the propor-
tion of retracting/reflecting growth cones (S-220 vs control:
54.3 	 10.8% vs 88.8 	 8.7%, p  0.0306, unpaired Student’s t
test; Fig. 3G).
The elevation of Epac2 activity by S-220 modulates
LPS-activated astrocytes and microglia
To assess whether S-220 has an effect in preventing and/or mod-
ulating the activation of the astrocytes and microglia in vitro, we
performed a simultaneous treatment study in which S-220 was
given at the same time with 10 g/ml LPS. Previous experiments
in the laboratory demonstrated that the treatment of 10 g/ml
LPS for 4 h allowed rapid activation of the microglia and astro-
cytes cells without inducing apoptosis (Georgieva, 2018).
The mean GFAP expression of astrocytes treated with LPS
(Fig. 4B) was increased compared with controls (Fig. 4A) (LPS vs
control: 27.9 	 1.8 vs 18.4 	 0.9, p  3  106, one-way
ANOVA, Bonferroni’s post hoc; Fig. 4G). The simultaneous treat-
ment of LPS and S-220 (Fig. 4C) showed a significant reduction
of GFAP intensity compared with LPS-treated astrocytes (LPS

Figure 5. The hydrogel degrades gradually, inducesminimal immune response, and supportsmarked neurite outgrowth in 2-dimentional cultures. A, An image of a freshly prepared gel.B, The
Griess assay showed low levels of nitrite ingel culturemedia comparedwith that of LPS-exposedprimarymicroglia cultures.C, Gel stiffness showedagradual decrease ingainmodulus fromthe linear
region of the raw data (0–100 Hz, rheology). D, In vitro cumulative percentage drug release versus time profile. Optimization of RGD concentration to promote neurite outgrowth of DRG explants
in twodimensions. E, DRG explant in gelwithout RGD. F, DRG explant in 1.6mMRGDgel.G, Quantification ofmaximal distance of neurite outgrowth showed significant differences at 1.6 and 3.2mM
RGD compared with control.H, Quantification of neurite densities of DRG explants at different concentrations of RGD. I, Cortical neurons on gel without RGD. J, Cortical neurons on gel with 1.6 mM
RGD. K, Quantification of neurite length in gels with andwithout RGD, showing significantly enhanced neurite outgrowth on gels with 1.6mM RGD. L, DRG explants grew extensive neurites in three
dimensions within the gel with 1.6 mM RGD at 72 h after plating. M, Z-stack image of DRG neurons growing in three dimensions within the 1.6 mM RGD gel. N, Z-plane view of DRG neurons. DRG
explantswere immunostained for GAP-43 (E, F ). DRGneurons and cortical neuronswere immunostained for-tubulin-III (I, J,M,N ). Data aremean	 SEM.n 3/group. Scale bars: E, F, 200m;
I, J, L, 100m;M, 50m.One-wayANOVAwithBonferroni’spost hoc (B,D,G,H ), Kruskal–Wallis ANOVAonRankswith Tukeypost hoc (C), andunpaired Student’s test (K ): *p0.05; **p0.01;
***p 0.001.
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S220 vs LPS: 20.7	 0.8 vs 27.9	 1.8, p
2 104, one-wayANOVA, Bonferroni’s
post hoc; Fig. 4G), being not significantly
different from that of the control ones
(LPS 
 S220 vs control: 20.7 	 0.8 vs
18.4 	 0.9, p  0.57, one-way ANOVA,
Bonferroni’s post hoc; Fig. 4G). Astrocyte
morphology was different within groups.
LPS-treated astrocytes (Fig. 4B) became
reactive, characterized by hypertrophic
processes, broader cell bodies, and tend to
cluster together. When astrocytes were si-
multaneously exposed to LPS and S-220
(Fig. 4C), they preserved nonreactive
morphology with slender processes simi-
lar to that of the control (Fig. 4A).
Microglia reactivity was quantified as
the percentage of iNOS marker immuno-
reactivity. The percentage of iNOS ex-
pression of microglia treated with LPS
(Fig. 4E) was increased compared with
controls (Fig. 4D) (LPS vs control: 45.8	
2.9 vs 4	 1.3, p 1.5 1016, one-way
ANOVA, Bonferroni’s post hoc; Fig. 4H).
The simultaneous treatment of LPS and
S-220 (Fig. 4F) showed a significant re-
duction of percentage of iNOS expression
compared with LPS-treated microglia
(LPS 
 S220 vs LPS: 24.7 	 3.8 vs 45.8 	 2.9, p  3.4  106,
one-way ANOVA, Bonferroni’s post hoc; Fig. 4H), being also
significantly different from that of the control ones (LPS
 S220
vs control: 24.7 	 3.8 vs 4 	 1.3, p  6.1  106, one-way
ANOVA, Bonferroni’s post hoc; Fig. 4H). Moreover, the simulta-
neous treatment of LPS and S-220 showed a significant reduction
of nitrite release compared with LPS-treated microglia (LPS 

S220 vs LPS: 0.7 	 0.2 vs 11.8 	 0.9, p  0.0002, unpaired
Student’s t test; Fig. 4I).
Fmoc-based hydrogel shows suitable properties for spinal
cord repair
Self-assembling Fmoc-based hydrogel was used as a delivery depot
for S-220 agonist and, therefore, its suitability for spinal repair
needed to be tested. The hydrogel (Fig. 5A) at 2.5 mM had a
stiffness of 100 Pa (Fig. 5C). We found that the hydrogel de-
graded gradually in vitro in PBS at 37°C, which wasmanifested by
the reduction in gel stiffness (H(2)  95.27, p  2  10
14,
Kruskal–Wallis ANOVA on Ranks with Tukey post hoc; Fig. 5C)
and gel mass over time (one-way ANOVA (F(4,25) 50.087, p
1.4  1011 with Bonferroni’s post hoc; data not shown). Mini-
mal activation of gel-exposed microglia was found by measuring
nitrite release in culture media, contrasting to the significant ni-
trite release observed using activating agent LPS alone (Fig. 5B).
Using fluorescein, which has a similar molecular weight com-
pared with the Epac2 agonist, we estimated the cumulative
release of the agonist from the hydrogel (Perale et al., 2012;Wilems
and Sakiyama-Elbert, 2015). The hydrogel showed a two-phase
release profile over a 28 d period (i.e., a quick release during the
first 7 d followed by a minimal gradual release over the next 3
weeks) (Fig. 5D). The hydrogel can also incorporate functional
motifs, such as arginine-glycine-aspartate (RGD) peptides to
promote cell adhesion (Zhou et al., 2009). Here, we demon-
strated that the hydrogel can be functionalized with RGD pep-
tides at different concentrations, with the 1.6 mM being the
optimal for neurite outgrowth (Dmax) of postnatal rat DRG ex-
plants (F(3,16) 7.06, p 0.003; No-RGD vs 1.6mMRGD: 535	
3 vs 975	 3m, p 0.0035; No-RGD vs 3.2mMRGD: 535	 29
vs 839	 60m, p 0.0039; one-way ANOVAwith Bonferroni’s
post hoc; Fig. 5E–H). At this optimal concentration of RGD, we
observed that the 2-D neurite outgrowth of dissociated postnatal
rat DRG neurons (i.e., maximal neurite length per neuron) was
comparable with that seen in gels without RGD (31.8 	 5.2 vs
24.5 	 3.8 m, p  0.137, unpaired Student’s t test; data not
shown). However, we found significantly increased 2-D neurite
outgrowth of postnatal rat cortical neurons with gels functional-
ized with 1.6mMRGD, compared with that of nonfunctionalized
gels (71.4 	 9.2 vs 17.3 	 4.3 m, p  1.2  106, unpaired
Student’s t test; Fig. 5I–K). Furthermore, we observed that the
functionalized hydrogel supported excellent 3-D neurite growth
of DRG explants and DRG neurons (Fig. 5L–N). For simplicity,
we refer to the hydrogel functionalized with 1.6 mM RGD here-
after as “the hydrogel.”
The elevation of Epac2 activity enhances 2-D neurite
outgrowth with Fmoc hydrogel in vitro
As a proof of concept, we first explored combination of the Epac2
activation strategy with the gel by adding the S-220 agonist in the
media of cultures where DRG explants or DRG neurons grew on
the gel surface. We demonstrated that there was a significant
increase in neurite outgrowth ofDRGexplants growing on the gel
and simultaneously treated with the agonist compared with that
with the gel alone [S-220 
 gel vs gel-only: 1141.4 	 159.9 vs
608.3	 93.9m(Dmax), p 0.029, unpaired Student’s t test; Fig.
6A–C]. In addition, we found that the neurite outgrowth of dis-
sociated DRG neurons was significantly enhanced by combining
S-220 and the gel comparedwith that of the gel alone [S-220
 gel
vs gel-only: 57.3 	 6.5 vs 31.9 	 5.3 m (mean total neurite
length per neuron), p  0.002, unpaired Student’s t test; Fig.
6D–F].
Figure 6. In vitro evidence demonstrating the positive effects of combining the Fmoc hydrogel with Epac2 agonist application
on neurite outgrowth. A–C, Assessing the effect of combining the Fmoc hydrogel with the Epac2 agonist S-220 in enhancing
neurite outgrowth of DRG explants. A, Control explant growing in gel alone.B, Explant growing in gel in combination with S-220.
C, Quantification of themaximal neurite length showed significantly longer neurites in the combination treatment group than the
gel-only group. D–F, Assessing the effect of combining the gel with S-220 in enhancing neurite outgrowth of dissociated DRG
neurons.D, DRG neurons growing in gel alone. E, DRG neurons growing in gel in combination with S-220. F, Quantification of
the maximal neurite length showed significantly longer neurites in the combination treatment group than the gel-only
group. DRG explants and neurons were immunostained for-tubulin-III. Data are mean	 SEM. Scale bars: A, 250m; B,
500m; D, E, 100m. Unpaired Student’s t test: *p 0.05; **p 0.01. n 3/group.
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Figure7. Timeline, studydesign, and schematic diagramof ex vivopreparation onorganotypic spinal cord culture.A, Timeline of the experiments.B, Schematic diagramdepicting theproduction
and lesioning of organotypic spinal cord slice cultures. Yellowdotted lines indicate a spinal cord slice. Red dotted lines and the red arrow indicate a lesion gap. C, Quantification of live/dead assay did
not show any difference before and after lesion (n 10–15/group). D, Representative live/dead-stained fluorescence micrograph of a slice before lesioning and 2 d after lesion. E–I, Using the ex
vivo model and -tubulin-III staining, we found that, at 7 d after injury, treatment with either S-220 or hydrogel alone produced similar degrees of neurite outgrowth into the lesion gaps, but
significantly more than that of the nontreated slices. E, Nontreated slice. F, S-220-treated slice.H, Hydrogel-treated slice. I, Combination-treated slice. White dashed lines indicate lesion margins.
The agonist was added to culturemedia.G, The axonal profile analysis showed that, when the gel was combinedwith S-220, there was significantly more axon growth in the lesion gap than those
following treatmentswith S-220 or hydrogel alone. C, Data aremean	 SEM.G, Data aremean	 SEM (box limits). Bars above and below each box represent 5%and 95% confidence limits. Circles
represent individual biological replicates (n 4–6). One-way ANOVA, Bonferroni’s post hoc test: *p 0.05; **p 0.01; ***p 0.001. Scale bars: D, 500m; E–I, 200m.
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The elevation of Epac2 activity promotes axonal outgrowth in
an ex vivo model of SCI
To further demonstrate the potential of Epac2 activation for spi-
nal cord repair, we adapted a previously establishedmouse ex vivo
model of SCI using postnatal rat spinal cord organotypic slices
(Weightman et al., 2014). The study design, timeline, and sche-
matic diagram of the methodology are shown in Figure 7A, B.
First, we used a live/dead assay to measure the viability of the
slices. The results showed that there was no difference in the
percentage of cells labeled by the cell death marker before and
after lesioning the slices (8.4 	 3.1 vs 4.6 	 2.1%, p  0.148,
unpaired Student’s t test; Fig. 7C,D).We then treated the lesioned
slices with S-220 being applied to the culture medium alone, or
S-220 applied to the culture medium together with hydrogels
(not containing S-220) being placed into lesion gaps (Fig. 7E–I).
One-way ANOVA showed that there was a significant treatment
effect on axonal outgrowth across the lesion gap among different
treatment groups (F(3,19) 8.547, p 0.0006; Fig. 7G). Thus, the
Figure8. S-220 incorporated into thehydrogel promotesneurite outgrowthand suppresses astrocyte activation.A,B, Representative images showing significant difference inneurite outgrowth
between gel-only (A) and gel
 5M S-220 (B). White dashed lines indicate lesionmargins. C, Neurite growth profiles across the lesion gap, showing a progressive increase with gel-only and gel

 5M S-220. D, Quantification showing the numbers of-tubulin-III
 processes per square millimeter between control and different concentrations of S-220 delivered in the gel, with 5M
having the greatest effect. E–G, Representative images exhibit astrocyte activation in the lesion using GFAP staining as an astrocyte marker. E, Control. F, Gel-only. G, Gel
 5 M S-220. H,
Quantification of the GFAP immunoreactivity intensity showed a significant reduction of mean gray value (optical density) in gel
 5 M S-220 compared with the control and the gel-only
treatment. I, Representative imageof the relationship betweenGFAP (red) and-tubulin-III (green) immunoreactive processes in a control injury condition. J, Higher-magnification image showing
the collapse of growth cones (white arrowheads) when they meet activated astrocytes. K, Representative image of the relationship between GFAP and-tubulin-III-immunoreactive processes in
a lesionwith combined treatmentwithgel
5MS-220.L, Higher-magnification image showing thealignmentof theastrocytes and-tubulin-III-immunoreactiveprocesses (white arrowheads).
M, N, Levels of astrocyte reactivity were estimated by the overlapping of GFAP (red) and nestin (green). M, Representative image of GFAP/nestin reactivity in lesion sites of nontreated slices. N,
Representative image of GFAP/nestin overlapping in slices treated with S-220 delivered by the hydrogel. O, Quantification of GFAP/nestin pixel overlapping. D, H, O, Data are mean	 SEM (box
limits). Bars above andbeloweachbox represent 5%and95%confidence limits. Circles represent individual biological replicates (n4–6). One-wayANOVAwithBonferroni’spost hoc test: **p
0.01; ***p 0.001. Scale bars: A, B, E–G,M, N, 100m; I, K, 50m; J, L, 25m.
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results showed that the number of -tubulin-III staining profiles
per square millimeter per slice was significantly higher in the
slices treated with the agonist and the gel compared with those of
the control, gel alone, and S-220 alone groups [S-220 
 gel vs
control, S-220 alone, and gel alone: 3016.5 	 596.5 vs 821.8 	
102.9 (p  0.00055), 1247.9 	 73.7 (p  0.005), and 1694.7 	
82.9 (p 0.0481), one-way ANOVA with Bonferroni’s post hoc;
Fig. 7G].
Epac2 agonist incorporated into Fmoc hydrogel promotes
axonal outgrowth
Our next step was to incorporate S-220 into the gel so that the
agonist could be locally released and delivered to the injury site.
Since it is a different deliverymethod, we tested different concen-
trations of the agonist to identify the optimal concentration.
One-way ANOVA showed that there was a significant concentra-
tion effect on axonal outgrowth across the lesion gap (F(2,12) 
21.53, p  0.00011; Fig. 8D). Thus, the results showed that the
number of -tubulin-III staining profiles per square millimeter
per slice was significantly higher in the slices treated with the gel

 S-220 (5M) compared with those of the gel
 S-220 (2.5M)
and gel
 S-220 (10 M) [gel
 S-220 (5 M) vs gel
 S-220 (2.5
M) or gel 
 S-220 (10 M): 3613.0 	 177.0 vs 1457.6 	 284.6
(p  0.000091) or 2289.8 	 298.2 (p  0.0086), one-way
ANOVA with Bonferroni’s post hoc test; Fig. 8A–D]. Once the
optimal concentration of the agonist was established, we then
investigated the efficacy of the agonist at this concentration when
it was incorporated into the gel in promoting neurite outgrowth
Figure 9. S-220 incorporated into the gel suppresses microglia activation in lesioned spinal cord slice. A, Iba-1-immunoreactive cells inside the injury site in control lesion slices. White asterisks
indicate activatedmorphology. B, Iba-1-immunoreactive cells inside the injury site in combination-treated slices. Yellow arrowheads indicate restingmorphology. C, Noninjuredmicroglia. Yellow
arrowheads indicate resting morphology. D, Cell body perimeter was quantified and used as an indication of activation. Cell body size decreased more significantly in the presence of the
hydrogel-only or hydrogel
 5M S-220, respectively. E, Representative image of the relationship between GFAP- and Iba-1-immunoreactive cells in an injured control. F, Representative image
of the relationship between GFAP- and Iba-1-immunoreactive cells in injured slices treated with a combination of hydrogel
 5M S-220. D, Data are mean	 SEM (box limits). Bars above and
beloweach box represent 5%and95%confidence limits. Circles represent individual biological replicates (n 4). One-wayANOVAwith Bonferroni’s post hoc test: **p 0.01; ***p 0.001. Scale
bars: A–C, 25m; E, F, 50m.
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across the lesion gap. One-way ANOVA showed that there was a
significant treatment effect on axonal outgrowth among different
experimental groups (F(4,22) 21.14, p 7 10
8; Fig. 8A–D).
Thus, the results showed that the number of -tubulin-III stain-
ing profiles per square millimeter per slice was significantly
higher in the slices treated with the gel
 S-220 (5M) compared
with those of the control and gel-only groups [gel
 S-220 (5M)
vs control or gel-only: 3613	 177 vs 743	 81.5 (p 3 108)
or 1698.5 	 169.4 (p  0.000003), Bonferroni’s post hoc; Fig.
8A–D].
The elevation of Epac2 activity attenuates the activation of
astrocytes in
an ex vivomodel of SCI
GFAP staining intensity within the lesion gap was quantified to
assess astrocyte reactivity. A marked difference was found in the
morphology of the astrocytes across the lesion gap from different
experimental groups. GFAP-immunoreactive cells at the fore-
front into the lesion gap in slices without any treatments were
intensively labeled and hypertrophic (Fig. 8E). Slices treated with
the gel-only presented amixed pattern ofGFAP-immunoreactive
cells (Fig. 8F), whereas those slices receiving S-220 treatment
delivered by the gel presented GFAP-immunoreactive cells that
were lightly labeled and had elongated polygonal morphologies
(Fig. 8G). One-way ANOVA showed that there was a significant
treatment effect on GFAP activation across the lesion gap among
different experimental groups (F(2,15) 76.79, p 1 10
7; Fig.
8H). Thus, the results showed that GFAP intensity in the slices
treated with the agonist and the gel was significantly lower than
those of the control or gel alone groups [gel
 S-220 vs control or
gel-only: 18.2	 1.1 vs 33.5	 0.5 (p 8 108) or 25.7	 0.9
(p 0.00004), one-way ANOVA Bonferroni’s post hoc test; Fig.
8H]. We then performed double staining for -tubulin-III and
GFAP to study the relationship between astrocytes (hypertrophic
and nonhypertrophic) and regrown neurites. In nontreated
slices, highly reactive astrocytes appeared to act as a barrier for
neurite outgrowth (Fig. 8I). Higher-magnification images dem-
onstrated collapsed growth cones when they confronted highly
reactive astrocytes (Fig. 8J). Conversely, in the slices receiving
S-220 delivered by the gel, we observed a close relationship be-
tween -tubulin-III-stained neurite profiles and GFAP-stained
astrocyte processes (Fig. 8K).Higher-magnification images dem-
onstrated that regrown axons were indeed aligned to astrocyte
processes (Fig. 8L).
Overlapping of nestin and GFAP markers was also quantified
as a reactivity parameter as previously described (O’Neill et al.,
2017). One-way ANOVA showed that there was a significant
treatment effect on nestin/GFAP overlapping across the lesion
gap among different experimental groups (F(2,16)  11.6, p 
0.0001; Fig. 8O). Thus, the results showed that the mean nestin/
GFAP overlapping pixels were significantly lower in the slices
treated with S-220 delivered by the gel, compared with those of
the control or gel alone groups [gel 
 S-220 vs control or gel-
only: 48,369.4	 16,194.2 vs 140,811.6	 12,992.8 (p 0.003) or
141,925.5 	 19,180.4 (p  0.002), Bonferroni’s post hoc; Fig.
8M–O].
The elevation of Epac2 activity attenuates microglial
activation in an ex vivomodel of SCI
We used the Iba-1 marker to identify microglia in lesioned slices.
We found that, within the lesion site, Iba-1-immunoreactive cells
displayed a highly activated morphology (large in cell size and
with noprocesses) in those sliceswithout any treatments (Fig. 9A,
white asterisks). This activated morphology was in contrast to
those Iba-1-immunoreactive cells located in themain body of the
slices away from the lesion margins (Fig. 9C, yellow arrowheads)
that exhibited a nonactivated morphology (small in cell size and
with ramified processes). However, we observed that, in those
slices treated with S-220 delivered by the gel, Iba-1-immuno-
reactive cells within the lesion site resembled the nonactivated
morphology seen in the main slice body (Fig. 9B, yellow arrow-
heads). We then performed a quantification to determine the
differences in Iba-1-immunoreactive cells within the lesion site
among different experimental groups bymeasuring cell body pe-
rimeter, which has been shown to correlate with microglial acti-
vation (Kozlowski and Weimer, 2012). Thus, the results showed
that the mean cell body perimeter of Iba-1-immunoreactive cells
per slice was significantly smaller in the slices treated with S-220
and the gel compared with those of the control or gel alone
groups [gel
 S-220 vs control or gel alone: 93	 4.2 vs 123.7	
1.7 m (p  0.000091) or 103.1 	 2.3 m (p  0.0086), Bon-
ferroni’s post hoc test; Fig. 9D]. In those slices receiving S-220
delivered by the gel, we found that the mean cell body perimeter
of Iba-1-immunoreactive cells was similar to that of nonactivated
microglia seen in the main slice body (gel 
 S-220 vs nonacti-
vatedmicroglia in themain slice body: 93	 4.2 vs 81.7	 2.4m,
p  0.115, unpaired Student’s t test; Fig. 9D). The relationship
between GFAP-immunoreactive and Iba-1-immunoreactive
cells was investigated by examining the colabeling of these two
markers. In nontreated slices, we observed that highly reactive
astrocytes were intermingled with large, amoeboid, and congre-
gated Iba-1-immunoreactive cells (Fig. 9E), demonstrating that
both activated glial cells formed a highly inhibitory environment
for neurite outgrowth. In contrast, in the slices receiving S-220
delivered by the gel, we observed smaller nonactivated Iba-1-
immunoreactive cells, which were sparsely spread around elon-
gated polygonal GFAP-immunoreactive cells (Fig. 9F).
S-220 delivered by Fmoc hydrogel promotes functional
recovery after a spinal cord contusion injury
Injured rats treatedwith S-220 delivered by the gel at 3weeks after
surgery showed significant improvement in the BBB score, al-
ready detectable 3 weeks after treatment compared with injury-
only controls, indicating better controlled limb movements after
treatment with S-220-loaded gels (Fig. 10). The improvements
Figure10. S-220 delivered by Fmoc hydrogel into the lesion of contusion injured spinal cord
enhances locomotor functional recovery. Both S-220-treatedandnontreated contusion-injured
animals showed similar levels of locomotor function at 3 weeks after injury as assessed on the
BBB open field task. However, by 2 weeks after treatment (indicated by the black arrow),
S-220-treated animals showed significantly better locomotor function (3 points on the BBB
scale) compared with the nontreated animals; a difference was maintained until 4 weeks after
treatment (the last timepoint assessed). Datawere analyzedwith two-wayANOVA followedby
Bonferroni’s post hoc test: *p 0.05. n 4 or 5. Data are mean	 SEM.
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were sustained for the rest of the study. Two-way ANOVA
showed that there were significant treatment effects (F(1,35) 
16.17, p 0.001; Fig. 10). Atweek 4 after treatment, contused rats
that received S-220-loaded gel significantly increased locomotor
behavior, reaching an average BBB score of 17.3	 0.9, compared
with 14.3	 1.1 for injury-only controls (p 0.042, Bonferroni’s
post hoc analysis; Fig. 10).
Discussion
Promoting injured adult CNS mammalian neurons to regrow
after injury remains a significant challenge in modern medicine.
Among different strategies, cAMP and its downstream effectors
have been shown to enhance neurons’ outgrowth capacity. Here,
we demonstrate, for the first time, using pharmacological and
genetic tools, that specific elevation of Epac2 activity, a down-
stream target of cAMP, significantly enhances neurite outgrowth
of cultured postnatal DRG and cortical neurons. Moreover,
Epac2 activation promotes significant axonal outgrowth in le-
sioned spinal cord slices in an ex vivo model of SCI. We reveal
novel evidence that Epac2 elevation overcomes inhibition on
neuron/axon growth by CSPGs and mature astrocytes in vitro
and by the postlesion environment of the ex vivomodel.
Previously PKA was thought to be
solely responsible for cAMP’s effects on
axonal growth (Siddiq and Hannila,
2015). However, strong evidence suggests
that it is Epac, not PKA, that mediates the
positive effects of cAMP in promoting ax-
onal growth (Murray et al., 2009; Boom-
kamp et al., 2014;Wei et al., 2016). Several
general agonists were developed to acti-
vate Epac, but not PKA, allowing the
study of Epac’s roles in mediating specific
cAMP functions in cell signaling pathways
(Enserink et al., 2002). Studies using these
agonists demonstrate that Epac mediates
cAMP-dependent axonal growth in: (1)
embryonic, neonatal, and adult rat DRG
neurons (Murray and Shewan, 2008;
Murray et al., 2009; Wei et al., 2016); (2)
PC12 cells (Christensen et al., 2003); and
(3) an in vitro model of SCI and remyeli-
nation (Boomkamp et al., 2014). These
agonists also regulate axonal elongation
in rat embryonic hippocampal neurons
(Mun˜oz-Llancao et al., 2015), and switch
the proliferative signal of cAMP to a neu-
ronal differentiation program in PC12
cells (Kiermayer et al., 2005). However,
they failed to discriminate the effects be-
tween Epac1 and Epac2.
We previously showed that siRNA
knockdown of Epac1 and Epac2 in adult
DRG neurons significantly reduced neu-
rite outgrowth (Murray and Shewan,
2008). However, since adult neurons
mainly express Epac2, our previous evi-
dence on neurite growth is likely to beme-
diated solely by Epac2. Here, we used an
Epac2 specific agonist (S-220), which has
been shown to selectively activate Epac2
(Schwede et al., 2015). We are the first
group to report the use of this agonist in
primary postnatal rat neurons and spinal
cord tissue. Indeed, we used FRET to demonstrate that S-220
enhanced Epac2 protein activity in the growth cones of DRG
neurons. Furthermore, we provided direct evidence that DRG
neurons turned toward a gradient of S-220, such that Epac2 ac-
tivation was biased toward the direction of turning. These data
convincingly suggest the specificity of this agonist in postnatal
neurons. We and others have previously reviewed potential
mechanisms of Epac2 signaling in neurite outgrowth (Peace and
Shewan, 2011; Batty et al., 2017). Thus, Epac2 is known to acti-
vate Rap1, which can subsequently modulate AKT (Mei et al.,
2002; Nijholt et al., 2008) and B-Raf-MER-ERK (Qiu et al., 2000;
Enserink et al., 2002; Wang et al., 2006) signaling pathways, both
being shown to play essential roles in axonal growth and guidance
(Liu and Snider, 2001). Epac2 activation may also lead to CREB
activation that has been shown to promote neuroplasticity (Wei
et al., 2016) (Fig. 11).
Following SCI, there are numerous molecules present at the
lesion site, including CSPGs, MAG, Nogo, and OMgp, which are
inhibitory to axonal outgrowth (Hannila and Filbin, 2008). A
body of evidence has shown that elevation of neuronal cAMP
level overcomes the inhibition by MAG and CNS myelin on ax-
Figure 11. A schematic diagram summarizing the potentialmechanisms of Epac2 activation by S-220 in the in vitro and ex vivo
studies. Blue dotted rectangle and blue dotted arrows represent themechanisms for in vitro studies. Red dotted rectangle and red
dotted arrows represent themechanisms for ex vivo studies. Our findings from the in vitro studies with individual monocultures of
neurons, astrocytes, and microglia demonstrate that S-220 has direct and individual effects on the following: (a) neurons, pro-
moting their growth possibly via the subsequent activation of Rap 1/B-Raf/ERK signaling pathway (Murray and Shewan, 2008;
Murray et al., 2009;Wei et al., 2016); (b) astrocytes, reducing their activation by LPS possibly via the IL-6/STAT3 signaling pathway
(Takanaga et al., 2004); and (c) microglia, reducing their activation by LPS possibly via arginase I signaling pathway (Ghosh et al.,
2016). S-220 binds to the cyclic nucleotide binding (CNB) domains of Epac2 protein within these cells, triggering downstream
signalingpathways (Tucker, 2014). Our findings fromthe ex vivo studies, however, suggest that S-220manifests its effects on these
cells in a more complex and intermingled manner as follows: (1) elongated astrocytes following S-220 treatment may resemble
radial glial progenitors, releasingaxon-growth supportingmolecules (Garcia et al., 2004); (2) elongatedastrocytes followingS-220
treatmentmay provide direct guidance for axonal growth (Anderson et al., 2016; Robichaux and Cheng, 2018); reduced astrocyte
activation by S-220may lead to upregulate the gene for NMDA receptor subunit NR2C, which is a key part in the tripartite synapse
regulating astrocyte–neuron communication (Paco et al., 2016); (4) reduced astrocyte activation by S-220may downregulate the
genes responsible for the production of proteoglycans, including CSPGs, thereby reducing their inhibitory effects on axonal out-
growth (Paco et al., 2016); (5) reduced astrocyte activation by S-220 may involve STAT3/nestin, and subsequently may regulate
other inflammatory cell behavior, such as that of microglia at the spinal cord lesion site (Wanner et al., 2013); and (6) reduced
microglial activation via astrocyte regulation may lead to reduced production of proinflammatory mediators (Steininger et al.,
2011), thereby promoting axonal outgrowth. It is also highly likely that S-220mayhave direct and individual effects on these three
types of cells in the ex vivomodel, including transcriptional changes in arginase I, IL-6, secretory leukocyte protease inhibitor, and
metallothionein in neurons (d) (Hannila and Filbin, 2008; Siddiq and Hannila, 2015), which have been shown to promote axonal
outgrowth and overcome inhibitory molecules. Red and blue small circles with diagonal across represent “stop/inhibit”. Green
arrows represent “promote/enhance”; ERK extracellular signal-regulated kinases; STAT3 signal transducer and activator of
transcription 3; IL-6 interleukin 6; NMDA N-methyl-D-aspartate.
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onal outgrowth (Siddiq and Hannila, 2015). The ability of cAMP
elevation to overcome inhibition may involve the activation of
CREB, which then leads to transcriptional changes in arginase I,
interleukin-6, secretory leukocyte protease inhibitor, and metal-
lothionein (Hannila and Filbin, 2008; Siddiq andHannila, 2015).
Upregulation of these genes has been shown to promote axonal
outgrowth (Cafferty et al., 2004; Deng et al., 2009; Ghasemlou et
al., 2010; Siddiq and Hannila, 2015). Here, we report that activa-
tion of Epac2 overcomes inhibition by CSPGs and mature astro-
cytes on neuronal growth, and this could therefore be mediated
through CREB activation. It is important to note that Rap1 can
regulate integrins, which are essential for cell adhesion (Bos et al.,
2003). Different cell types have been shown to control adhesion
to laminin via cAMP-mediated integrin regulation (Murphy et
al., 2005). Therefore, Epac2 activation could possibly also lead to
Rap1-mediated redistribution and conformational activation of
integrins in the growth cone (Bos et al., 2003), therebymodifying
their responses to inhibitorymolecules in the extracellularmatrix
after injury (Condic et al., 1999; Tan et al., 2011; Cheah and
Andrews, 2018).
Apart from the effects on axonal outgrowth in the ex vivo
model, we also report a significantly modified lesion environ-
ment consisting of astrocytes andmicroglia by the Epac2 agonist.
Astrocytes form the major cell type that contribute to the forma-
tion of the glial scar after SCI, and strong evidence suggests that
there is heterogeneity within astrocyte populations in the scar
with some cells producing axon-growth supporting molecules
(Anderson et al., 2016). The morphology of Epac2 agonist-
treated astrocytes in our study remarkably resembles those newly
proliferated and elongated astrocytes at the lesion border after
SCI, which are regulated by the STAT3 signaling pathway (Wan-
ner et al., 2013) and show similarity with radial glial progenitors
providing guidance for neuron growth during CNS development
(Garcia et al., 2004). Although the functions of these elongated
astrocytes at the lesion border are largely unclear, evidence sug-
gests that they regulate inflammatory cell behavior (Wanner et
al., 2013).Here, we demonstrate a similar pattern following S-220
treatment, in that elongated astrocytes exist among Iba-1
 mi-
croglia with nonactivated morphology at the lesion site. It is
known that cAMP elevation can cause autocrine interleukin-6
upregulation in astrocytes, which in turn can lead to STAT3
phosphorylation (Takanaga et al., 2004).Moreover, cAMP eleva-
tion in astrocytes causes morphological change into a process-
bearing shape, downregulation of the genes responsible for
proteoglycan production, and upregulation of the gene for the
NMDA receptor subunit NR2C that is a major component of the
tripartite synapse regulating astrocyte–neuron communication
(Paco et al., 2016). Therefore, it is conceivable that in our study
the S-220 has caused profound changes in astrocytes at the lesion
site similar to those described after cAMP elevation and render
them supportive for the regrowing axons (Fig. 11). Furthermore,
there is evidence that cAMP elevation by a general agonist causes
microglial BV-2 cells to increase arginase I production and
change to bipolar morphology when cotreated with TNF-
(Ghosh et al., 2016). Epac activation by a general agonist also
causes BV-2 cells to reduce their proinflammatory activities
(Steininger et al., 2011). Hence, we propose that in our study the
S-220 also attenuates the activation of microglia at the lesion site.
Together, our data suggest that Epac2 elevation in both astrocytes
and microglia may have potently modified the lesion environ-
ment from inhibitory to permissive for axonal outgrowth.
With the novel Fmoc-based hydrogel used as a delivery depot
for sustained release of S-220, our study confers translational
potential. We demonstrate, for the first time, that this hydrogel
has excellent biocompatibility and supports excellent neurite
outgrowth in vitro and axonal outgrowth in the ex vivo model.
Moreover, its stiffness can be tuned to be similar to CNS tissue
properties, which is a key requirement for spinal cord repair
(Georges et al., 2006). Furthermore, the hydrogel can be devel-
oped as injectable formats that can fully plug lesion cavities, thus
representing a minimally invasive neurosurgical technique
(Cigognini et al., 2011; Kabu et al., 2015). In an exploratory pilot
study, we injected the S-220-loaded Fmoc hydrogel into the le-
sion cavity of rats with contusion SCI at a subacute stage (i.e., 3
weeks after injury) and found significantly improved locomotor
functional recovery compared with animals with contusion only.
However, further in vivo immunohistochemical and functional
studies are required to validate the potential of these treatments
in SCI, which is beyond the scope of the current study. Future
studies also need to further optimize the injected hydrogel vol-
ume and S-220 dose and establish the in vivo effects of S-220 on
axonal outgrowth and glial activation.
The failure to find a cure for spinal cord repair ismainly due to
the complex injury nature of SCI. Many studies have designed
strategies, either alone or in combination, to tackle various ob-
stacles presented by the injury, but so far have failed to translate
results to the clinic. Our findings using Epac2 elevation to pro-
mote spinal cord repair underpin a significant game change not
only in directly enhancing the intrinsic capacity of injured neu-
rons to regrow, but moreover in harnessing the inhibitory envi-
ronment, including the glial scar and microglia, to facilitate
axonal outgrowth. However, caution is needed when extrapolat-
ing our strategy to other CNS injuries, such as brain injury and
stroke, as recent preclinical evidence suggests that, in the acute
phase of hemorrhage-induced brain trauma, increased neuronal
expression of Epac2 leads to apoptosis (Zhuang et al., 2019).
Future studies are required to fully understand the role of Epac2
under different CNS injury pathogeneses.
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